SCLC

January 19, 2024

Why Atezolizumab and Chemotherapy Should Be Used with Caution in Real-World SCLC Population

Atezolizumab, a programmed death-ligand 1 (PD-L1) inhibitor, has shown promising results in clinical trials when combined with chemotherapy for the treatment of extensive-stage small cell lung cancer (ES-SCLC). However, a real-world evaluation of atezolizumab plus platinum-etoposide chemotherapy in patients with ES-SCLC in Canada raises important considerations regarding its use.
Why Atezolizumab and Chemotherapy Should Be Used with Caution in Real-World SCLC Population
This website uses cookies to improve your experience. By using this website you agree to our Cookie Policy.
Read more